Cardioline s.p.a.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cardioline s.p.a. - overview
Established
1962
Location
Trento, -, Italy
Primary Industry
Software
About
Cardioline s. p. a. is an Italian medical technology company specializing in advanced diagnostic cardiac solutions, providing essential tools for healthcare professionals to facilitate accurate cardiac assessments.
Founded in 1962 in Trento, Italy, Cardioline s. p. a. develops advanced cardiac diagnostic solutions.
In November 2021, ArchiMed acquired a majority stake in the company, enhancing its strategic direction. Notably, Sandra Antoniazzi founded the company, contributing to its growth in the diagnostic cardiology sector. The firm has carried out a significant deal in recent years, with the latest transaction occurring on November 17, 2021. Cardioline specializes in advanced diagnostic cardiac solutions, leveraging over 60 years of expertise in diagnostic cardiology and more than a decade in telecardiology.
The company offers a range of modular products designed to meet the diverse needs of healthcare providers across various settings, including hospitals, emergency care, private practices, and point-of-care facilities. Key offerings include Resting ECG systems, which utilize advanced algorithms and user-friendly interfaces for comprehensive cardiac analysis; innovative stress testing tools for evaluating cardiac function; and Holter monitoring devices that provide 24/7 heart activity tracking. These solutions are designed for healthcare professionals, addressing critical needs in accurate diagnosis and ongoing patient care. Cardioline's products are distributed across multiple international markets, specifically targeting regions in Europe, Asia, and the Middle East.
In 2023, Cardioline reported a revenue of USD 19. 56 mn and an EBITDA of USD 2. 20 mn, generated primarily through direct sales to healthcare institutions and professionals. The company's focus on B2B relationships allows hospitals and clinics to purchase equipment for diagnostic and monitoring purposes, further supported by partnerships with distributors to enhance market reach.
The revenue stream is complemented by recurring sales of consumables and maintenance services associated with its diagnostic equipment. Cardioline s. p. a.
aims to expand its product offerings and market presence, both organically and through acquisitions. The company plans to introduce new products designed to enhance diagnostic capabilities, with specific launch timelines to be determined. Additionally, there are intentions to penetrate new markets, with targeted regions including Asia and the Middle East by 2025. Recent funding will support these initiatives, allowing Cardioline to advance its growth strategy effectively.
Current Investors
ARCHIMED
Primary Industry
Software
Sub Industries
Healthcare IT, Monitoring Equipment, Medical Software, Storage Management Software
Website
www.cardioline.it
Verticals
HealthTech, Manufacturing, Mobile Apps
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Cardioline s.p.a. - timeline of key events
Cardioline s.p.a. - financials
| Fiscal Year Ended | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 5,244,605 | 5,938,654 | 5,938,654 | 7,319,241 | 8,153,873 | 8,153,873 | 8,759,070 | 10,370,476 | 12,493,876 | 14,522,028 | - | - | - |
| % Revenue Growth (YoY) | - | 13.2% | - | 23.2% | 11.4% | - | 7.4% | 18.4% | 20.5% | 16.2% | - | - | - |
| EBITDA (USD) | 205,850 | (409,894) | (409,894) | 327,189 | 635,993 | 761,061 | 247,412 | 1,531,250 | 1,425,229 | 1,759,020 | - | - | - |
| Operating Income (USD) | 128,924 | (574,650) | (574,650) | (148,062) | (235,814) | (235,814) | (954,339) | 125,612 | 274,321 | 656,293 | - | - | - |
| Operating Margin | 2.5% | (9.7%) | (9.7%) | (2.0%) | (2.9%) | (2.9%) | (10.9%) | 1.2% | 2.2% | 4.5% | - | - | - |
| % EBITDA Margin | 3.9% | (6.9%) | (6.9%) | 4.5% | 7.8% | 9.3% | 2.8% | 14.8% | 11.4% | 12.1% | - | - | - |
| NET Income (USD) | 26,789 | (626,884) | (626,884) | (238,814) | (308,647) | (308,647) | (1,098,486) | 4,496 | 157,782 | 435,407 | - | - | - |
| % Net Margin | 0.5% | (10.6%) | (10.6%) | (3.3%) | (3.8%) | (3.8%) | (12.5%) | 0.0% | 1.3% | 3.0% | - | - | - |
Cardioline s.p.a. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out | Completed | Cardios | - | ||||||||
| Buyout | Completed | Cardioline s.p.a. | - |
Displaying 1 - 2 of 2
Cardioline s.p.a. - employee data
Cardioline s.p.a. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| President of the Board of Auditors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.